Novartis Issues Update On Radioligand Therapy Production

Novartis (NVS) said, in early June, the company restarted radioligand therapy production at its sites in Ivrea, Italy, and Millburn, New Jersey, and resumed delivery of doses to patients in a phased approach. Novartis expects that product supply may be initially limited.

The company has also restarted screening and enrollment for clinical trials with 177Lu-PSMA-617 in the US, in most countries globally, and clinical trials with Lutathera in the US and Canada.

Novartis said it is investing in the expansion of radioligand therapy production capabilities in both Millburn and Ivrea, as well as building a new radioligand manufacturing facility in Indianapolis, Indiana that will be operational in 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing company Lyft announced its foray into the media and advertisement business with the launch of Lyft Media as part of its vision to build the world's largest transportation media network. Lyft Media has built a suite of new products to allow advertisers to engage with Lyft's growing audience throughout their transportation journeys. Sysco Corp. (SYY) Tuesday reported a more than a three-times surge in fourth-quarter earnings, supported by 17.5 percent growth in sales. The company projects fiscal 2023 adjusted earnings to grow. Earnings for the quarter spiked to $509.99 million from $151.09 million last year. On a per share basis,... Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22.
Follow RTT